While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.

People who have an inflammatory bowel disease like ulcerative colitis often have problems caused by inflammation in other parts of their bodies. One of these is a skin condition called pyoderma ...

On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative skin disease, following the trial’s early ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...